Home > News > Headline News > Archive

Click on title to read the full article.

JNM: PET imaging of estrogen receptors is diagnostic for breast cancer

January 31, 2012

By Health Imaging

With the exception of liver metastases, whole-body imaging of estrogen receptor (ER) expression with 18F-FES, an ER-specific PET tracer, can be a valuable additional diagnostic tool when standard work-up is inconclusive, particularly in breast cancer patients, according to a study published in the February issue of the Journal of Nuclear Medicine.

Studies Reignite Debate over Avastin in Breast Cancer

January 27, 2012

By MedPage

Women with HER2-negative metastatic breast cancer had significantly higher rates of pathologic complete response (pCR) when bevacizumab (Avastin) was added to neoadjuvant chemotherapy, two large clinical trials showed.

Circulating Tumor Cells: The Ultimate Assay?

January 22, 2012

By Cinical Oncology News

What Is the Current Standard of Care for Anti-HER2 Neoadjuvant Therapy in Breast Cancer?

January 20, 2012

By Gunter von Minckwitz, MD, Sibylle Loib, MD, Michael Untch, MD2

Neoadjuvant treatment with a sequential anthracycline-taxane–based chemotherapy in combination with trastuzumab(Drug information on trastuzumab) (Herceptin) is currently a preferred therapy for patients with HER2-positive breast cancer.

Breast Cancer Cells Targeted, Then Burned, by Gold-Filled Silicon Wafers

January 20, 2012

By Science Daily

By shining infrared light on specially designed, gold-filled silicon wafers, scientists at The Methodist Hospital Research Institute have successfully targeted and burned breast cancer cells.

CLEOPATRA: Success With Dual HER2 Blockade in Breast Cancer

January 8, 2012

By ElsGlobalMedicalNews

At Last - Possible Therapy for Brain Metastasis Brain metastasis thwarted with pigment epithelium derived factor Reviewed By: Jo

January 7, 2012

By Laurie Stoneham

Progress is being made on most oncology fronts. Unfortunately, brain metastasis remains something medicine hasn't touched in an effective way. Researchers may have found a new opening in resolving the greatest challenge women with advanced breast cancer face.

Generex Subsidiary Antigen Express Provides Update on AE37 Cancer Vaccine's Clinical & Regulatory Strategy

January 7, 2012

By Generex Biotechnology Corporation

Positive interim results from Phase 2b breast cancer study of AE37 presented last month at a major scientific breast cancer conference enable update to clinical development & regulatory strategy and the potential for earlier completion of key scientific milestone